Complicated urinary tract infection with Extensive Drug resistant Klebsiella pneumoniae treated with combinatorial therapy of CSE-1034 along with Carbapenems. A case report and the review of literature
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i11.26782Keywords:
Catheter-associated urinary tract infections, Carbapenems, Extended spectrum beta lactamases, Metallo-beta-lactamasesAbstract
Colistin is considered one of the last available therapeutic options to treat infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP).
However, with an increase in the use of colistin to treat CRKP infections, colistin resistance is emerging and there are no standard treatment regimens
for these type of infections. In the present case report, we are discussing a case of 64-year-old male patient having complicated urinary tract infection
(cUTI) by CRKP, treated successfully with ceftriaxone+sulbactam+EDTA (CSE-1034) and carbapenem combination therapy. Conclusively, CSE-1034 in
combination with or without carbapenems could be a successful therapeutic option for the treatment of CRKP cUTI cases.
Downloads
References
Al-Hazmi H. Role of duration of catheterization and length of hospital stay on the rate of catheter-related hospital-acquired urinary tractinfections. Res Rep Urol 2015;7:41-7.
Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58:256-60.
Paterson DL, Harris PN. Colistin resistance: A major breach in our last line of defence. Lancet Infect Dis 2016;16:132-3.
Giani T, Arena F, Vaggelli G, Conte V, Chiarelli A, Henrici De Angelis L, et al. Large nosocomial outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae traced to clonal expansion of an Mgrb deletion mutant. J Clin Microbiol 2015;53:3341-4.
Suh JY, Son JS, Chung DR, Peck KR, Ko KS, Song JH. Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. Antimicrob Agents Chemother 2010;54:560-2.
Moemen D, Masallat DT. Prevalence and characterization of carbapenem-resistant Klebsiella pneumoniae isolated from intensive care units of Mansoura University hospitals. Egypt J Basic Appl Sci 2017;4:37-41.
El-mahdy TS, Abdelaziz MO, El-domany RA. Prevalence and molecular characterization of extended spectrum β-lactamases in Klebsiella pneumoniae isolates from cancer patients and others. Int J Pharm Pharm Sci 2015;7:122-7.
Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 2015;13:42-51.
Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: A potential threat. JAMA 2008;300:2911-13.
Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, et al. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University hospital: Molecular characterization, epidemiology, and outcomes. Clin Infect Dis Off Publ Infect Dis Soc Am 2010;50:364 73.
Woodford N, Zhang J, Warner M, Kaufmann ME, Matos J, Macdonald A, et al. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J Antimicrob Chemother 2008;62:1261-4.
Iacovelli V, Gaziev G, Topazio L, Bove P, Vespasiani G, Agrò F, et al. Nosocomial urinary tract infections: A review. Riv Urol 2014;81:222-7.
Shah PG, Shah SR, Kamat SD, Kamat DV. Colistin-carbapenem combination therapy against carbapenem resistant gram negative bacilli infections: Clinical and an in vitro synergy study. Int J Pharm Pharm Sci 2014;6:497-500.
Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzarlis K, Zakynthinos E, et al. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: Mechanisms of resistance, molecular identification and epidemiological data. BMC Infect Dis 2015;15:559.
Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007;30:525 9.
Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011;55:593-9.
Gao R, Hu Y, Li Z, Sun J, Wang Q, Lin J, et al. Dissemination and mechanism for the MCR-1 colistin resistance. PLOS Pathog 2016;12:e1005957.
Wanty C, Anandan A, Piek S, Walshe J, Ganguly J, Carlson RW, et al. The structure of the neisserial lipooligosaccharide phosphoethanolamine transferase A (LptA) required for resistance to polymyxin. J Mol Biol 2013;425:3389-402.
Nordmann P, Nass T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2017;17:1791-8.
Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: Report from the SENTRY antimicrobial surveillance program, 2006-2007. Antimicrob Agents Chemother 2011;55:1274-8.
Ashour HM, El-Sharif A. Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients. J Transl Med 2009;7:14.
Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602.
Charan J, Mulla S, Ryavanki S, Kantharia N. New Delhi metallo-beta lactamase-1 containing Enterobacteriaceae: Origin, diagnosis, treatment and public health concern. Pan Afr Med J 2012;11:22.
Swaminathan A, Ardra M, Manoharan A, Nair KP, Girija KR. Characterisation of carbapenemase-producing gram-negative bacilli among clinical isolates in a tertiary care centre in Kerala, South India. J Acad Clin Microbiol 2016;18:100.
Nagaraj S, Chandran SP, Shamanna P, Macaden R. Carbapenem resistance among Escherichia coli and Klebsiella pneumoniae in a tertiary care hospital in south India. Indian J Med Microbiol 2012;30:93.
Dwivedi M, Mishra A, Azim A, Singh RK, Baronia AK, Prasad KN, et al. Ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae carrying multiple metallo-beta-lactamase genes. Indian J Pathol Microbiol 2009;52:339-42.
Solanki R, Vanjari L, Subramanian S, Aparna B, Nagapriyanka E, Lakshmi V, et al. Comparative evaluation of multiplex PCR and routine laboratory phenotypic methods for detection of carbapenemases among gram negative bacilli. J Clin Diagn Res 2014;8:DC23-6.
Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011;55:3002-4.
Shameem M, Mir MA. Management of pneumonia and blood stream infections with new antibiotic adjuvant entity (ceftriaxone + sulbactam + disodium edetate) - A novel way to spare carbapenems. J Clin Diagn Res 2016;10:LC23-7.
Chaudhary M, Mir MA, Ayub SG, Protocol 06 Group. Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: A post-marketing surveillance study. Braz J Infect Dis Off Publ Braz Soc Infect Dis 2017;21:408-17.
Chaudhary M, Ayub SG, Mir MA. Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia. J Infect Public Health 2018;11:691-7.
Sahu M, Sanjith S, Bhalekar P, Keny D. Waging war against extended spectrum beta lactamase and metallo betalactamase producing pathogens-novel adjuvant antimicrobial agent Cse1034- an extended hope. J Clin Diagn Res 2014;8:DC20-3.
Bhatia P. Alternative empiric therapy to carbapenems in management of drug resistant gram negative pathogens: A new way to spare carbapenems. Res J Infect Dis 2015;3:2.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
